Literature DB >> 7643137

Molecular diagnosis of hereditary neuropathy with liability to pressure palsies (HNPP) by detection of 17p11.2 deletion in Italian patients.

P Mandich1, R James, S Nassani, R Defferrari, E Bellone, G Mancardi, A Schenone, M Abbruzzese, M Rocchi, F Ajmar.   

Abstract

Hereditary neuropathy with a liability to pressure palsies (HNPP) is an autosomal dominant disorder characterized by recurrent pressure palsies generally precipitated by minor trauma; weakness and paraesthesia usually improve and recover completely in a few months. By Southern blotting and fluorescent in situ hybridization analysis we confirm the presence of a 17p11.2 deletion in familial and in isolated cases of HNPP, suggesting that molecular analysis of the 17p11.2 region could also be a reliable and non-invasive method of diagnosis in sporadic cases, where a correct diagnosis usually requires a nerve biopsy. Although HNPP is a mild disease and not all patients seek medical attention, a presymptomatic diagnosis is useful for assessing the risk during genetic counselling, due to the inheritance of the mutation.

Entities:  

Mesh:

Year:  1995        PMID: 7643137     DOI: 10.1007/BF00878871

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

1.  HEREDITARY NEUROPATHY, WITH LIABILITY TO PRESSURE PALSIES; A CLINICAL AND ELECTROPHYSIOLOGICAL STUDY OF FOUR FAMILIES.

Authors:  C J EARL; P M FULLERTON; G S WAKEFIELD; H S SCHUTTA
Journal:  Q J Med       Date:  1964-10

Review 2.  An inherited DNA rearrangement and gene dosage effect are responsible for the most common autosomal dominant peripheral neuropathy: Charcot-Marie-Tooth disease type 1A.

Authors:  J R Lupski
Journal:  Clin Res       Date:  1992-12

3.  Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies.

Authors:  P J Dyck; E H Lambert
Journal:  Arch Neurol       Date:  1968-06

4.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

5.  Molecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplication.

Authors:  C A Wise; C A Garcia; S N Davis; Z Heju; L Pentao; P I Patel; J R Lupski
Journal:  Am J Hum Genet       Date:  1993-10       Impact factor: 11.025

6.  Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A.

Authors:  J R Lupski; C A Wise; A Kuwano; L Pentao; J T Parke; D G Glaze; D H Ledbetter; F Greenberg; P I Patel
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

7.  A yeast artificial chromosome contig spanning the Charcot-Marie-Tooth disease type 1A duplication region.

Authors:  B W Nieuwenhuijsen; K L Chen; A C Chinault; S Wang; V H Valmiki; E J Meershoek; G J van Ommen; K H Fischbeck
Journal:  Hum Mol Genet       Date:  1992-11       Impact factor: 6.150

8.  Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families.

Authors:  E Bellone; P Mandich; G L Mancardi; A Schenone; A Uccelli; M Abbruzzese; A Sghirlanzoni; D Pareyson; F Ajmar
Journal:  J Med Genet       Date:  1992-07       Impact factor: 6.318

9.  Further evidence of a duplication in 17p11.2 in families with recurrence of HMSN Ia (Charcot-Marie-Tooth neuropathy type Ia).

Authors:  E Müller; M L Mostacciuolo; G Micaglio; C Angelini; G A Danieli
Journal:  Hum Genet       Date:  1992-11       Impact factor: 4.132

10.  Hereditary motor and sensory neuropathy with calf hypertrophy is associated with 17p11.2 duplication.

Authors:  A Uncini; A Di Muzio; F Chiavaroli; D Gambi; M Sabatelli; N Archidiacono; R Antonacci; R Marzella; M Rocchi
Journal:  Ann Neurol       Date:  1994-05       Impact factor: 10.422

View more
  1 in total

Review 1.  The PMP22 gene and its related diseases.

Authors:  Jun Li; Brett Parker; Colin Martyn; Chandramohan Natarajan; Jiasong Guo
Journal:  Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.